Elanco Misled Investors About Dog Medicine Safety, Suit Says

By Rae Ann Varona

An Elanco investor lodged a proposed securities class action against the animal pharmaceutics company on Monday, telling a Maryland federal court that the company misled investors about the safety of a canine dermatitis treatment it was developing and its timelines for drug launches.

 Complaint attached | Read full article » | Save to favorites »